var data={"title":"Oprelvekin (United States: Not available): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oprelvekin (United States: Not available): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6686?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oprelvekin-united-states-not-available-drug-information\" class=\"drug drug_general\">see &quot;Oprelvekin (United States: Not available): Drug information&quot;</a> and <a href=\"topic.htm?path=oprelvekin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oprelvekin (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709182\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Oprelvekin has caused allergic or hypersensitivity reactions, including anaphylaxis. Permanently discontinue administration of oprelvekin in any patient who develops an allergic or hypersensitivity reaction.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203860\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Neumega [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2738290\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Biological Response Modulator</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Thrombopoietic Growth Factor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2738300\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=oprelvekin-united-states-not-available-drug-information\" class=\"drug drug_general\">see &quot;Oprelvekin (United States: Not available): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Neumega has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:0em;\">SubQ: <b>Note:</b> First dose should not be administered until 6-24 hours after the end of chemotherapy. Discontinue the drug at least 48 hours before beginning the next cycle of chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 25-50 mcg/kg once daily for 27 days was shown to be efficacious with decreased toxicities as compared to higher doses in one study with 47 pediatric patients (Cairo, 2005); dosing should continue until postnadir platelet count &ge;50,000/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The manufacturer states that, until efficacy/toxicity parameters are established, the use of oprelvekin in pediatric patients (particularly those &lt;12 years of age) should be restricted to use in controlled clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 50 mcg/kg once daily for 10-21 days (until postnadir platelet count &ge;50,000/mm<sup>3</sup>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal failure:</b> Adults: CrCl &lt;30 mL/minute: 25 mcg/kg once daily for 10-21 days (until postnadir platelet count &ge;50,000/mm<sup>3</sup>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203844\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neumega: 5 mg (1 ea [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203828\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49660521\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Neumega has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2738361\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer subcutaneously in either the abdomen, thigh, hip, or upper arm (if not self-injected). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203856\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials (and prefilled diluent syringe) refrigerated between 2&deg;C and 8&deg;C (36&deg;F and 46&deg;F); do not freeze. Protect from light. Store reconstituted solution in the vial at either 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) or room temperature of &le;25&deg;C (77&deg;F); use within 3 hours of reconstitution. Do not freeze or shake reconstituted solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2738291\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203884\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oprelvekin may be confused with aldesleukin, Proleukin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neumega may be confused with Neulasta, Neupogen</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203882\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial arrhythmia, cardiomegaly (children), edema, palpitations, syncope, tachycardia (more common in children), vasodilataion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache, insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Fluid retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, mucositis, nausea, oral candidiasis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (dilutional; onset: 3 to 5 days; duration: &le;1 week), febrile neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, periosteal disease (children), severe weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctival edema (more common in children), conjunctival erythema (more common in children), conjunctival injection (more common in children),  papilledema (more common  in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, pharyngitis, pleural effusion, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Amblyopia, anaphylactoid reaction, anaphylaxis, blindness, blurred vision, capillary leak syndrome, cardiac failure, cerebrovascular accident, chest pain, decreased visual acuity, dehydration, dysarthria, exfoliative dermatitis, facial edema, hemophthalmos, hypersensitivity reaction, hypervolemia, hypoalbuminemia, hypocalcemia, hypokalemia, hypotension, increased clotting factors (von Willebrand factor), increased serum fibrinogen, injection site reaction (dermatitis, local discoloration, pain at injection site), loss of consciousness, mental status changes, optic neuropathy, paresthesia, pericardial effusion, peripheral edema, pneumonia, pulmonary edema, renal failure, shock, skin discoloration, urticaria, ventricular arrhythmia, visual field defect, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203850\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to oprelvekin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203832\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anemia (dilutional): Dilutional anemia may occur due to increased plasma volume, presenting as moderate decreases in hemoglobin concentration, hematocrit, and red blood cells without a decrease in red blood cell mass; effect generally appears within 3 to 5 days of initiation of therapy and resolves over ~1 week following oprelvekin discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: Arrhythmias (usually brief in duration), pulmonary edema, and cardiac arrest have been reported; use in patients with a history of atrial arrhythmia only if the potential benefit exceeds possible risks. Stroke has been reported in patients who develop atrial fibrillation/flutter while receiving oprelvekin (patients with a history of stroke or transient ischemic attack may be at risk for atrial fibrillation/flutter). Ventricular arrhythmia has also been reported, occurring within 2 to 7 days of treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fluid retention: May cause serious fluid retention (reversible within several days after discontinuation), which may result in peripheral edema, dyspnea, pulmonary edema, capillary leak syndrome, atrial arrhythmias, and exacerbation of preexisting pleural effusion. Serious fluid retention (sometimes fatal) has been reported. Use with caution in patients with clinically evident heart failure or who may be susceptible to developing heart failure, patients receiving aggressive hydration, patients with a history of heart failure who are well compensated and receiving appropriate medical therapy, and patients who may develop fluid retention as a result of associated medical conditions or whose medical condition may be exacerbated by fluid retention. Monitor fluid and electrolyte status; preexisting fluid collections, including pericardial effusions or ascites, should also be monitored (may require drainage).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: <b>[US Boxed Warning]: Allergic or hypersensitivity reactions, including anaphylaxis, have been reported. Permanently discontinue in any patient developing an allergic or hypersensitivity reaction.</b> Reaction may occur with the first or with subsequent doses. Allergic reactions included facial/tongue/larynx edema, dyspnea, wheezing, chest pain, hypotension (including shock), rash, urticaria, flushing, fever, loss of consciousness, mental status changes, and/or dysarthria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Papilledema: Papilledema has occurred, usually following repeated cycles. The incidence of papilledema occurred more frequently in children. Use with caution in patients with preexisting papilledema or with CNS tumors; may worsen or develop during treatment. Patients experiencing oprelvekin-related papilledema may be at risk for visual acuity changes and/or visual field defects, ranging from blurred vision to blindness.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment (oprelvekin is renally eliminated); dosage adjustment required in severe renal impairment. Monitor fluid balance. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Begin 6 to 24 hours following completion of chemotherapy; safety and efficacy of oprelvekin administered immediately before or during cytotoxic chemotherapy or initiated at the time of expected nadir has not been established. Not indicated following myeloablative chemotherapy; increased toxicities (hypotension, tachycardia, edema, and conjunctival bleeding) were reported and efficacy was not demonstrated. A higher incidence of adverse events (fluid retention/overload, facial/pulmonary edema, capillary leak syndrome) has also been reported when used following bone marrow transplantation. Efficacy has not been evaluated with chemotherapy regimens &gt;5 days' duration or with regimens associated with delayed myelosuppression (eg, nitrosoureas, mitomycin). Safety and efficacy have not been established with chronic administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26019897\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Reported adverse events that occurred more frequently in children than adults include tachycardia (84%), conjunctival injection (57%), cardiomegaly (21%), and periosteal changes (11%). Papilledema (dose-limiting) also reported more frequently in children than adults (16% vs 2%).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299793\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203837\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12946&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203840\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3277319\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2738362\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor electrolytes and fluid balance during therapy; obtain a CBC at regular intervals during therapy; monitor platelet counts until adequate recovery has occurred; renal function (at baseline) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203831\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Oprelvekin is a thrombopoietic growth factor that stimulates megakaryocytopoiesis and thrombopoiesis, resulting in proliferation of megakaryocyte progenitors and megakaryocyte maturation, thereby increasing platelet production.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203849\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 5 to 9 days; Maximum effect: 14 to 19 days  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: Up to 7 days after discontinuation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Adults: 112 to 152 mL/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: &gt;80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: 6.9 &plusmn; 1.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 3.2 &plusmn; 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (primarily; predominantly as metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: Adults: 2.2 to 2.7 mL/min/kg; clearance decreases with age and is about 1.2 to 1.6 times faster in children than in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323558\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Neumega Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $528.92</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539907\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Jijufen (CN);</li>\n      <li>Neumega (KR);</li>\n      <li>Plaquemax (BR);</li>\n      <li>Yi Xing (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adams VR and Brenner TL, &ldquo;Oprelvekin (Neumega&reg;),&rdquo; <i>J Oncol Pharm Pract</i>, 1999, 5(3):117-24. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cairo MS, Davenport V, Bessmertny O, et al, &quot;Phase I/II Dose Escalation Study of Recombinant Human Interleukin-11 Following Ifosfamide, Carboplatin and Etoposide in Children, Adolescents and Young Adults With Solid Tumours or Lymphoma: A Clinical, Haematological and Biological Study,&quot; <i>Br J Haematol</i>, 2005, 128(1):49-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oprelvekin-united-states-not-available-pediatric-drug-information/abstract-text/15606549/pubmed\" target=\"_blank\" id=\"15606549\">15606549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Du X and Williams DA, &ldquo;Interleukin-11: Review of Molecular, Cell Biology, and Clinical Use,&rdquo; <i>Blood</i>, 1997, 89(11):3897-908. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oprelvekin-united-states-not-available-pediatric-drug-information/abstract-text/9166826/pubmed\" target=\"_blank\" id=\"9166826\">9166826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gordon MS, &ldquo;Thrombopoietic Activity of Recombinant Human Interleukin 11 in Cancer Patients Receiving Chemotherapy,&rdquo; <i>Cancer Chemother Pharmacol</i>, 1996, 38 (Suppl):96-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oprelvekin-united-states-not-available-pediatric-drug-information/abstract-text/8765426/pubmed\" target=\"_blank\" id=\"8765426\">8765426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milman E, Berdon WE, Garvin JH, et al, &quot;Periostitis Secondary to Interleukin-11 (Oprelvekin, Neumega&reg;). Treatment for Thrombocytopenia in Pediatric Patients,&quot; <i>Pediatr Radiol</i>, 2003, 33(7):450-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oprelvekin-united-states-not-available-pediatric-drug-information/abstract-text/12728286/pubmed\" target=\"_blank\" id=\"12728286\">12728286</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tepler I, Elias L, Smith JW 2d, et al, &ldquo;A Randomized Placebo-Controlled Trial of Recombinant Human Interleukin-11 in Cancer Patients With Severe Thrombocytopenia Due to Chemotherapy,&rdquo; <i>Blood</i>, 1996, 87(9):3607-14. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oprelvekin-united-states-not-available-pediatric-drug-information/abstract-text/8611684/pubmed\" target=\"_blank\" id=\"8611684\">8611684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teramura M, Kobayashi S, Yoshinaga K, et al, &ldquo;Effect of Interleukin 11 on Normal and Pathological Thrombopoiesis,&rdquo; <i>Cancer Chemother Pharmacol</i>, 1996, 38 (Suppl):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oprelvekin-united-states-not-available-pediatric-drug-information/abstract-text/8765427/pubmed\" target=\"_blank\" id=\"8765427\">8765427</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12946 Version 77.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709182\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F203860\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F2738290\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F2738300\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F203844\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F203828\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49660521\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2738361\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F203856\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2738291\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F203884\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F203882\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F203850\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F203832\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26019897\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299793\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F203837\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F203840\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3277319\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2738362\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F203831\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F203849\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323558\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539907\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12946|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oprelvekin-united-states-not-available-drug-information\" class=\"drug drug_general\">Oprelvekin (United States: Not available): Drug information</a></li><li><a href=\"topic.htm?path=oprelvekin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Oprelvekin (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}